Ocugen Stock News

Ocugen, Inc. (NASDAQ:OCGN) CEO Shankar Musunuri sold 115,000 shares of the companys stock in a transaction that occurred on Thursday, December 16th. The stock was sold at an average price of $5.22, for a total transaction of $600,300.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC []

Can they both win in the coronavirus vaccine space?

Related Stocks: OCGN ,

Meme stocks run the gamut from senseless to sensible. These seven unfortunately fall in the former camp, so steer clear.

Ocugen, Inc. (NASDAQ:OCGN) with the stream of -7.38% also noticed, India Synchrony Financial (NYSE:SYF) encountered a rapid change of 1.93% in the last hour of Thursdays trading session. Ocugen, Inc. The post Abnormal volume spikes: Ocugen, Inc. (NASDAQ:OCGN), Synchrony Financial (NYSE:SYF) appeared first on Stocks Equity .

InvestorPlace - Stock Market News, Stock Advice & Trading Tips With its Covid-19 vaccine catalyst vanishing, the best move hasn''t changed with OCGN stock avoid. The post As Covaxin Catalyst Fades, Stay Away From Ocugen Stock appeared first on InvestorPlace . More From InvestorPlace Stock Prodigy Who Found NIO at $2 Says Buy THIS Now Man Who Called Black Monday: Prepare Now. #1 EV Stock Still Flying Under the Radar Interested in Crypto? Read This First

InvestorPlace - Stock Market News, Stock Advice & Trading Tips This time last year, Ocugen traded below 30 cents. Up 1,683% since, owners of OCGN stock ought to be grateful for their unexpected returns. The post Christmas Is a Time for Ocugen Shareholders to Give Thanks appeared first on InvestorPlace . More From InvestorPlace Stock Prodigy Who Found NIO at $2 Says Buy THIS Now Man Who Called Black Monday: Prepare Now. #1 EV Stock Still Flying Under the Radar Interested in Crypto? Read This First

Results from a study suggest that Covaxin could be effective in coronavirus variants of concern.

With its Covid-19 vaccine catalyst vanishing, the best move hasn't changed with OCGN stock — avoid. The post As Covaxin Catalyst Fades, Stay Away From Ocugen Stock appeared first on InvestorPlace.

This time last year, Ocugen traded below 30 cents. Up 1,683% since, owners of OCGN stock ought to be grateful for their unexpected returns.

MALVERN, Pa., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics and vaccines, announced that data analyzing immune response following two doses of the vaccine candidate, COVAXIN (BBV152), from a third-party study were published on the preprint server, medRxiv . The data compared the immune memory response of 71 vaccinated and 73 naturally infected subjects with SARS-CoV-2, including variants of concern, for up to six months. The study found that COVAXIN (BBV152) generated a robust immune memory against spike and nucleoprotein that was comparable to that following natural COVID-19 infection for the levels of antibodies, memory B cells and memory CD4+ T cells.

One analyst believes the outlook for electric vehicle (EV) stocks in 2022 won't offer the same support it has during the current year. The post EV Stocks Outlook for 2022: Why One Analyst Sees Investo

Ocugen Inc (NASDAQ: OCGN) announced that immune response data following two doses of Covaxin from a third-party study were published on the preprint server, medRxiv.  The data compared the immune

Ocugen, Inc. (NASDAQ:OCGN) with the stream of -9.25% also noticed, India AT&T Inc. (NYSE:T) encountered a rapid change of -0.67% in the last hour of Tuesdays trading session. Ocugen, Inc. The post Eye-catching Shares: Ocugen, Inc. (NASDAQ:OCGN), AT&T Inc. (NYSE:T) appeared first on Stocks Equity .